ConductScience.org, home

Paper42730438

Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study.

Sawaf B and 10 others. Crohns Colitis 360, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study. Papers, record 42730438. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42730438

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study.
PubMed
Journal
Crohns Colitis 360
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-14
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sawaf BBisherhttps://orcid.org/0000-0001-6751-619X
2Battistin UUmberto
3Abu-Rumaileh MMohammed
4Gerges KMKyrillos Mahroushttps://orcid.org/0000-0002-6899-238X
5Hallak YYusufhttps://orcid.org/0000-0002-1695-7750
6Abbarh SShahemhttps://orcid.org/0000-0001-6812-2192
7Batikh EElias
8Hadaki NNwal
9Elhadi MMuhammedhttps://orcid.org/0000-0001-6406-4212
10Regueiro MMiguelhttps://orcid.org/0000-0002-7681-8111
11Al-Haddad MMohammadhttps://orcid.org/0000-0003-1641-9976

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140260307Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients.Crohns Colitis 3602025https://conductscience.org/library/papers/40260307PubMed
236975373Significant Racial and Ethnic Disparities Exist in Health Care Utilization in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Inflamm Bowel Dis2024https://conductscience.org/library/papers/36975373PubMed
333935763Novel and Emerging Therapies for Inflammatory Bowel Disease.Front Pharmacol2021https://conductscience.org/library/papers/33935763PubMed
435644155
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet2022https://conductscience.org/library/papers/35644155PubMed
531944255Disease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus.Inflamm Bowel Dis2020https://conductscience.org/library/papers/31944255PubMed
623964933Vedolizumab as induction and maintenance therapy for Crohn's disease.N Engl J Med2013https://conductscience.org/library/papers/23964933PubMed
735644154Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.Lancet2022https://conductscience.org/library/papers/35644154PubMed
830097359
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet2018https://conductscience.org/library/papers/30097359PubMed
936058820Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis.Dig Liver Dis2023https://conductscience.org/library/papers/36058820PubMed
1029507339Socioeconomic Status and Race are both Independently associated with Increased Hospitalization Rate among Crohn's Disease Patients.Sci Rep2018https://conductscience.org/library/papers/29507339PubMed
1133512666Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.Dermatol Ther (Heidelb)2021https://conductscience.org/library/papers/33512666PubMed
1223075178Ustekinumab induction and maintenance therapy in refractory Crohn's disease.N Engl J Med2012https://conductscience.org/library/papers/23075178PubMed
1332617771Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications.Dig Dis Sci2021https://conductscience.org/library/papers/32617771PubMed
1429050646Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.Lancet2017https://conductscience.org/library/papers/29050646PubMed
1528411872Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.Lancet2017https://conductscience.org/library/papers/28411872PubMed
1627959607Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med2016https://conductscience.org/library/papers/27959607PubMed
1725116048Hemoglobin and hematocrit levels in the prediction of complicated Crohn's disease behavior--a cohort study.PLoS One2014https://conductscience.org/library/papers/25116048PubMed
1835573757Iron Deficiency Anemia: An Overlooked Complication of Crohn's Disease.J Hematol2022https://conductscience.org/library/papers/35573757PubMed
1928423301Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.N Engl J Med2017https://conductscience.org/library/papers/28423301PubMed
2039018531Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.N Engl J Med2024https://conductscience.org/library/papers/39018531PubMed

See all 25 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42730438

GET https://conductscience.org/api/papers/v1/42730438/references?page=2